Blockade of CCR5 to protect the liver graft in HIV/HCV co-infected patients

Journal of Hepatology

Volumn 59, Issue 3, 2013, Pages 613-615

  Haïm Boukobza, Stéphanie ^a,b,c,f   Balabanian, Karl ^b,c,f   Teicher, Elina ^b,c,d,f   Bourgeade, Marion ^b,c,f   Perlemuter, Gabriel ^c,e,f   Roque Afonso, Anne Marie ^a,b,c,f   Duclos Vallee, Jean Charles ^a,b,c,f  

^a HÔPITAL PAUL BROUSSE   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d BICÊTRE HOSPITAL   (France)

^e HÔPITAL ANTOINE BÉCLÈRE   (France)

^f DHU Hepatinov   (France)

Author keywords

CCR5; Fibrosis; Liver graft rejection; Liver transplantation; Maraviroc

Indexed keywords

CHEMOKINE RECEPTOR CCR5; MARAVIROC;

CHEMOTAXIS; DISEASES; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LIVER FIBROSIS; LIVER GRAFT; LIVER GRAFT REJECTION; MIXED INFECTION; NOTE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RELAPSE; T LYMPHOCYTE;

CCR5; FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MARAVIROC;

CHEMOTAXIS, LEUKOCYTE; CYCLOHEXANES; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; RECEPTORS, CCR5; T-LYMPHOCYTES; TRIAZOLES;

EID: 84882867274     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.03.034     Document Type: Note

References (15)

1. M. Fischereder, B. Luckow, B. Hocher, R.P. Wuthrich, U. Rothenpieler, and H. Schneeberger CC chemokine receptor 5 and renal-transplant survival Lancet 357 2001 1758 1761
2. W. Gao, K.L. Faia, V. Csizmadia, S.T. Smiley, D. Soler, and J.A. King Beneficial effects of targeting CCR5 in allograft recipients Transplantation 72 2001 1199 1205
3. J. Li, G. Chen, P. Ye, S. Wang, K. Zhang, and W. Chen CCR5 blockade in combination with cyclosporine increased cardiac graft survival and generated alternatively activated macrophages in primates J Immunol 186 2011 3753 3761
4. N.A. Terrault, M.E. Roland, T. Schiano, L. Dove, M.T. Wong, and F. Poordad Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection Liver Transpl 18 2012 716 726
5. S. Goddard, A. Williams, C. Morland, S. Qin, R. Gladue, and S.G. Hubscher Differential expression of chemokines and chemokine receptors shapes the inflammatory response in rejecting human liver transplants Transplantation 72 2001 1957 1967
6. C. Heidenhain, G. Puhl, C. Moench, A. Lautem, and P. Neuhaus Chemokine receptor 5Delta32 mutation reduces the risk of acute rejection in liver transplantation Ann Transplant 14 2009 36 44
7. S. op den Dries, C.I. Buis, J. Adelmeijer, E.J. Van der Jagt, E.B. Haagsma, and T. Lisman The combination of primary sclerosing cholangitis and CCR5-Delta32 in recipients is strongly associated with the development of nonanastomotic biliary strictures after liver transplantation Liver Int 31 2011 1102 1109
8. C. Moench, A. Uhrig, A.W. Lohse, and G. Otto CC chemokine receptor 5delta32 polymorphism - a risk factor for ischemic-type biliary lesions following orthotopic liver transplantation Liver Transpl 10 2004 434 439
9. J.A. Pineda, M. Aguilar-Guisado, A. Rivero, J.A. Giron-Gonzalez, J. Ruiz-Morales, and D. Merino Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients Clin Infect Dis 49 2009 1274 1282
10. J.C. Duclos-Vallee, C. Feray, M. Sebagh, E. Teicher, A.M. Roque-Afonso, and B. Roche Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus Hepatology 47 2008 407 417
11. M. Zeremski, L.M. Petrovic, and A.H. Talal The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection J Viral Hepat 14 2007 675 687
12. W. Lin, E.M. Weinberg, A.W. Tai, L.F. Peng, M.A. Brockman, and K.A. Kim HIV increases HCV replication in a TGF-beta1-dependent manner Gastroenterology 134 2008 803 811
13. A.C. Tuyama, F. Hong, Y. Saiman, C. Wang, D. Ozkok, and A. Mosoian Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis Hepatology 52 2010 612 622
14. J. Macias, M.M. Viloria, A. Rivero, I. de los Santos, M. Marquez, and J. Portilla Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy Eur J Clin Microbiol Infect Dis 31 2012 2083 2088
15. P. Yeni, A. Lamarca, D. Berger, P. Cimoch, A. Lazzarin, and P. Salvato Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naive patients: results of the EPIC study (CCR100136) HIV Med 10 2009 116 124